Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 20 11:06AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.58 Insider Own47.40% Shs Outstand48.26M Perf Week7.95%
Market Cap68.77M Forward P/E- EPS next Y-1.22 Insider Trans0.00% Shs Float25.38M Perf Month7.14%
Income-70.09M PEG- EPS next Q-0.34 Inst Own30.05% Short Float5.97% Perf Quarter2.52%
Sales3.85M P/S17.86 EPS this Y15.95% Inst Trans-1.22% Short Ratio4.24 Perf Half Y-4.36%
Book/sh3.22 P/B0.44 EPS next Y10.95% ROA-43.11% Short Interest1.52M Perf Year-76.90%
Cash/sh3.26 P/C0.44 EPS next 5Y- ROE-48.28% 52W Range1.02 - 7.38 Perf YTD-27.66%
Dividend Est.- P/FCF- EPS past 5Y-7.46% ROI-43.36% 52W High-80.69% Beta0.39
Dividend TTM- Quick Ratio15.85 Sales past 5Y280.42% Gross Margin64.86% 52W Low39.71% ATR (14)0.08
Dividend Ex-Date- Current Ratio15.85 EPS Y/Y TTM13.62% Oper. Margin-1963.23% RSI (14)58.63 Volatility5.22% 5.94%
Employees43 Debt/Eq0.06 Sales Y/Y TTM-78.07% Profit Margin-1821.54% Recom1.00 Target Price9.50
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q14.69% Payout- Rel Volume0.29 Prev Close1.43
Sales Surprise-100.00% EPS Surprise17.02% Sales Q/Q-100.00% EarningsMay 13 AMC Avg Volume357.56K Price1.42
SMA206.80% SMA503.98% SMA200-42.42% Trades Volume29,871 Change-0.35%
Date Action Analyst Rating Change Price Target Change
Sep-22-23Initiated Wedbush Outperform $11
May-04-23Resumed H.C. Wainwright Buy $18
Dec-23-21Initiated H.C. Wainwright Buy $25
May-05-21Resumed Credit Suisse Outperform $30
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-20-21Initiated William Blair Outperform
Apr-20-21Initiated Jefferies Buy
Apr-20-21Initiated Credit Suisse Outperform $30
May-13-24 08:52PM
Apr-10-24 08:00AM
Mar-12-24 08:00AM
Feb-27-24 08:00AM
04:15PM Loading…
Feb-21-24 04:15PM
Feb-14-24 09:35AM
Jan-24-24 09:35AM
Jan-19-24 06:25AM
Jan-18-24 04:05PM
Nov-09-23 07:00AM
Nov-07-23 08:00AM
Sep-27-23 09:01AM
Sep-05-23 08:00AM
Aug-12-23 08:07AM
09:30AM Loading…
Aug-10-23 09:30AM
Aug-08-23 08:24AM
Aug-07-23 07:00AM
Jun-20-23 08:50AM
Jun-05-23 02:59PM
Jun-02-23 08:50AM
May-24-23 08:00AM
May-16-23 08:29AM
May-15-23 09:05AM
May-10-23 05:35PM
08:42AM Loading…
May-08-23 12:07PM
May-04-23 09:00PM
May-03-23 08:50AM
May-02-23 09:29PM
Apr-20-23 08:00AM
Apr-17-23 09:00AM
Mar-14-23 08:15AM
Mar-07-23 08:00AM
Mar-06-23 08:00AM
Mar-01-23 07:13AM
Feb-28-23 08:00AM
Dec-22-22 07:13AM
Dec-19-22 04:30PM
Nov-28-22 12:11PM
Nov-22-22 07:30AM
Nov-11-22 10:05AM
Nov-10-22 09:00AM
Nov-07-22 09:25AM
Oct-26-22 07:30AM
Oct-18-22 07:30AM
Oct-05-22 08:05AM
Sep-22-22 06:25AM
Sep-06-22 07:30AM
Aug-12-22 07:41AM
Aug-11-22 08:45AM
Jul-14-22 10:43AM
Jul-06-22 07:00AM
Jun-22-22 07:00AM
Jun-14-22 09:13AM
May-18-22 07:00AM
May-15-22 08:41AM
May-13-22 08:28AM
May-12-22 08:35AM
May-11-22 08:44AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-13-22 07:00AM
Apr-12-22 02:01PM
Mar-28-22 05:37PM
Mar-17-22 07:00AM
Mar-07-22 04:30PM
Mar-01-22 07:00AM
Feb-03-22 04:35PM
Jan-26-22 07:00AM
Dec-24-21 12:38AM
Dec-23-21 06:05AM
Dec-18-21 12:38AM
Dec-17-21 08:00AM
Dec-08-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 07:00AM
Nov-04-21 07:00AM
Nov-02-21 08:00AM
Oct-07-21 09:00AM
Oct-01-21 08:15AM
Sep-02-21 07:00AM
Aug-12-21 07:00AM
Jul-08-21 07:00AM
Jun-26-21 05:18AM
May-26-21 07:00AM
May-13-21 07:00AM
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.